Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc.
Healthy Vision Month in May is a great time for Texans to focus on protecting their vision health and preventing eye disease. To keep eyes healthy, schedule regular eye exams to check for common ...
LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after – – Continued favorable safety profile observed in masked ...
Gene therapy for neovascular age-related macular degeneration is linked to positive anatomical changes, but variable visual outcomes.
PulseSight Therapeutics has unveiled positive phase 1 results for PST‑611, its non‑viral gene therapy candidate for dry ...
PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive non-viral vectorized gene therapies with minimally-invasive delivery technology, has reported the ...
About Dr. James Leong: Dr. James Leong is an Oxford fellowship-trained consultant ophthalmologist specializing in medical retina, uveitis, and refractive cataract surgery. He is the founder of The Eye ...
Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease May 8, 2026 12:30 PM ...
A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show the treatment is safe and can significantly improve vision, even in severely ...
Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ...
Explore the major milestones of induced pluripotent stem cell (iPSC) research, from Shinya Yamanaka’s discovery to current ...
Phase 3 wet AMD trials, LUGANO and LUCIA, remain on track with topline data expected beginning mid-2026 -Phase 3 DME clinical trials, COMO and CAPRI, rapidly advancing with over one-third of patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results